COVID-19: Montreal Heart Institute concludes colchicine tablet is effective

Modesto Morganelli
Gennaio 25, 2021

Colchicine treatment reduced hospitalizations for patients in the study by 25%, reduced the need for mechanical ventilation by 50%, and reduced deaths by 44%.

"Our research shows the efficacy of colchicine treatment in preventing the "cytokine storm" phenomenon and reducing the complications associated with COVID-19", said Dr. Jean-Claude Tardif, principal investigator of the COLCORONA trial.

A study in Canada has shown that colchicine - a medicine used to treat gout - is "the world's first oral drug that could be used to treat non-hospitalised patients with Covid-19", says the Montreal Heart Institute. The study looked at its effects on 4,159 COVID-19 patients.

Colchicine is effective in preventing risky inflammatory syndromes called "cytokine storms" and reducing complications associated with Covid-19, said Dr Jean-Claude Tardif, director of the MHI Research Centre and principal investigator in this study.

Colchicine is now the only known effective oral medication for treating non-hospitalized COVID-19 patients - a world first, according to a press release issued by the Institute on January 23.

Patients involved needed to be over the age of 40 and have at least one risk factor for possible complications.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE